Hematopoietic stem cell gene therapy to halt neurodegeneration
- PMID: 39276677
- PMCID: PMC11417237
- DOI: 10.1016/j.neurot.2024.e00440
Hematopoietic stem cell gene therapy to halt neurodegeneration
Abstract
Microglia play fundamental roles in multiple pathological primary and secondary processes affecting the central nervous system that ultimately result in neurodegeneration and for this reason they are considered as a key therapeutic target in several neurodegenerative diseases. Microglia-targeted therapies are directed at either restoring or modulating microglia function, to redirect their functional features toward neuroprotection. Among these strategies, hematopoietic stem cell gene therapy have proven to be endowed with a unique potential for replacing diseased microglia with engineered, transplant progeny cells that can integrate and exert relevant beneficial effects in the central nervous system of patients affected by inherited and acquired neurodegenerative conditions.
Keywords: Gene therapy; Hematopoietic stem cells; Microglia.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alessandra Biffi reports a relationship with Orchard Therapeutics that includes: consulting or advisory and funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Haploinsufficiency at the CX3CR1 locus of hematopoietic stem cells favors the appearance of microglia-like cells in the central nervous system of transplant recipients.Nat Commun. 2024 Nov 25;15(1):10192. doi: 10.1038/s41467-024-54515-4. Nat Commun. 2024. PMID: 39587072 Free PMC article.
-
Hematopoietic Gene Therapies for Metabolic and Neurologic Diseases.Hematol Oncol Clin North Am. 2017 Oct;31(5):869-881. doi: 10.1016/j.hoc.2017.06.004. Epub 2017 Jul 23. Hematol Oncol Clin North Am. 2017. PMID: 28895853 Review.
-
Delivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases.ACS Chem Neurosci. 2019 Jan 16;10(1):18-20. doi: 10.1021/acschemneuro.8b00408. Epub 2018 Aug 23. ACS Chem Neurosci. 2019. PMID: 30136572 Review.
-
A comprehensive review of AAV-mediated strategies targeting microglia for therapeutic intervention of neurodegenerative diseases.J Neuroinflammation. 2024 Sep 19;21(1):232. doi: 10.1186/s12974-024-03232-2. J Neuroinflammation. 2024. PMID: 39300451 Free PMC article. Review.
-
Hematopoietic stem cell gene therapy for inherited bone marrow disorders: past accomplishments and continued challenges.J Cell Biochem Suppl. 2002;38:55-64. doi: 10.1002/jcb.10131. J Cell Biochem Suppl. 2002. PMID: 12046850 Review.
Cited by
-
Gene therapy for neurologic disorders.Neurotherapeutics. 2024 Jul;21(4):e00453. doi: 10.1016/j.neurot.2024.e00453. Neurotherapeutics. 2024. PMID: 39318035 Free PMC article. No abstract available.
-
Immune mechanisms and shared immune targets in neurodegenerative diseases.Nat Rev Neurol. 2025 Feb;21(2):67-85. doi: 10.1038/s41582-024-01046-7. Epub 2024 Dec 16. Nat Rev Neurol. 2025. PMID: 39681722 Review.
References
-
- Provenzano F., Perez M.J., Deleidi M. Redefining microglial identity in health and disease at single-cell resolution. Trends Mol Med. 2021;27:47–59. - PubMed
-
- Bottcher C., Schlickeiser S., Sneeboer M.A.M., Kunkel D., Knop A., Paza E., et al. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat Neurosci. 2019;22:78–90. - PubMed
-
- Sankowski R., Bottcher C., Masuda T., Geirsdottir L., Sagar, Sindram E., et al. Mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat Neurosci. 2019;22:2098–2110. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical